prikaz prve stranice dokumenta Temporal Dynamics of MOG Antibodies in Children With Acquired Demyelinating Syndrome
  Preuzmi
PDF 370.63 KB
Znanstveni rad - Izvorni znanstveni rad
Temporal Dynamics of MOG Antibodies in Children With Acquired Demyelinating Syndrome
Neurology - Neuroimmunology Neuroinflammation, 9 (2022), 6; e200035. https://doi.org/10.1212/NXI.0000000000200035
(BIOMARKER Study Group) Wendel, Eva Maria; Thonke, Helen Sophie; Bertolini, Annikki; Baumann, Matthias; Blaschek, Astrid; Merkenschlager, Andreas; Karenfort, Michael; Kornek, Barbara; Lechner, Christian; Pohl, Daniela; Pritsch, Martin; Schanda, Kathrin; Schimmel, Mareike; Thiels, Charlotte; Waltz, Stephan; Wiegand, Gert; Anlar, Banu; Barišić, Nina; Blank, Christian; Breu, Markus; Broser, Philip; Della Marina, Adela; Diepold, Katharina; Eckenweiler, Matthias; Eisenkölbl, Astrid; Freilinger, Michael; Gruber-Sedlmayr, Ursula; Hackenberg, Annette; Iff, Tobias; Knierim, Ellen; Koch, Johannes; Kutschke, Georg; Leiz, Steffen; Lischetzki, Grischa; Nosadini, Margherita; Pschibul, Alexander; Reiter-Fink, Edith; Rohrbach, Doris; Salandin, Michela; Sartori, Stefano; Schlump, Jan-Ulrich; Stoffels, Johannes; Strautmanis, Jurgis; Tibussek, Daniel; Tüngler, Victoria; Utzig, Norbert; Reindl, Markus; Rostásy, Kevin Više autora...

Citirajte ovaj rad

Wendel, E. M., Thonke, H. S., Bertolini, A., Baumann, M., Blaschek, A., Merkenschlager, A. ... Rostásy, K. (2022). Temporal Dynamics of MOG Antibodies in Children With Acquired Demyelinating Syndrome. Neurology - Neuroimmunology Neuroinflammation, 9. (6). doi: 10.1212/NXI.0000000000200035

Wendel, Eva Maria, et al. "Temporal Dynamics of MOG Antibodies in Children With Acquired Demyelinating Syndrome." Neurology - Neuroimmunology Neuroinflammation, vol. 9, br. 6, 2022. https://doi.org/10.1212/NXI.0000000000200035

Wendel, Eva Maria, Helen Sophie Thonke, Annikki Bertolini, Matthias Baumann, Astrid Blaschek, Andreas Merkenschlager, Michael Karenfort, et al. "Temporal Dynamics of MOG Antibodies in Children With Acquired Demyelinating Syndrome." Neurology - Neuroimmunology Neuroinflammation 9, br. 6 (2022). https://doi.org/10.1212/NXI.0000000000200035

Wendel, E. M., et al. (2022) 'Temporal Dynamics of MOG Antibodies in Children With Acquired Demyelinating Syndrome', Neurology - Neuroimmunology Neuroinflammation, 9(6). doi: 10.1212/NXI.0000000000200035

Wendel EM, Thonke HS, Bertolini A, Baumann M, Blaschek A, Merkenschlager A, i sur.. Temporal Dynamics of MOG Antibodies in Children With Acquired Demyelinating Syndrome. Neurology - Neuroimmunology Neuroinflammation [Internet]. 13.10.2022. [pristupljeno 12.04.2024.];9(6). doi: 10.1212/NXI.0000000000200035

E. M. Wendel, et al., "Temporal Dynamics of MOG Antibodies in Children With Acquired Demyelinating Syndrome", Neurology - Neuroimmunology Neuroinflammation, vol. 9, br. 6, Listopad 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:425317. [Citirano: 12.04.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:425317
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Temporal Dynamics of MOG Antibodies in Children With Acquired Demyelinating Syndrome
AutorEva Maria Wendel
AutorHelen Sophie Thonke
AutorAnnikki Bertolini
AutorMatthias Baumann
AutorAstrid Blaschek
AutorAndreas Merkenschlager
AutorMichael Karenfort
AutorBarbara Kornek
AutorChristian Lechner
AutorDaniela Pohl
AutorMartin Pritsch
AutorKathrin Schanda
AutorMareike Schimmel
AutorCharlotte Thiels
AutorStephan Waltz
AutorGert Wiegand
AutorBanu Anlar
AutorNina Barišić
AutorChristian Blank
AutorMarkus Breu
AutorPhilip Broser
AutorAdela Della Marina
AutorKatharina Diepold
AutorMatthias Eckenweiler
AutorAstrid Eisenkölbl
AutorMichael Freilinger
AutorUrsula Gruber-Sedlmayr
AutorAnnette Hackenberg
AutorTobias Iff
AutorEllen Knierim
AutorJohannes Koch
AutorGeorg Kutschke
AutorSteffen Leiz
AutorGrischa Lischetzki
AutorMargherita Nosadini
AutorAlexander Pschibul
AutorEdith Reiter-Fink
AutorDoris Rohrbach
AutorMichela Salandin
AutorStefano Sartori
AutorJan-Ulrich Schlump
AutorJohannes Stoffels
AutorJurgis Strautmanis
AutorDaniel Tibussek
AutorVictoria Tüngler
AutorNorbert Utzig
AutorMarkus Reindl
AutorKevin Rostásy
KolaboracijaBIOMARKER Study Group
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA PEDIJATRIJU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Pedijatrija
Sažetak (engleski)
Background and objective: The spectrum of myelin oligodendrocyte glycoprotein (MOG) antibody-associated disorder (MOGAD) comprises monophasic diseases such as acute disseminated encephalomyelitis (ADEM), optic neuritis (ON), and transverse myelitis and relapsing courses of these presentations. Persistently high MOG antibodies (MOG immunoglobulin G [IgG]) are found in patients with a relapsing disease course. Prognostic factors to determine the clinical course of children with a first MOGAD are still lacking. The objective of the study is to assess the clinical and laboratory prognostic parameters for a risk of relapse and the temporal dynamics of MOG-IgG titers in children with MOGAD in correlation with clinical presentation and disease course. Methods: In this prospective multicenter hospital-based study, children with a first demyelinating attack and complete data set comprising clinical and radiologic findings, MOG-IgG titer at onset, and clinical and serologic follow-up data were included. Serum samples were analyzed by live cell-based assay, and a titer level of ≥1:160 was classified as MOG-IgG-positive. Results: One hundred sixteen children (f:m = 57:59) with MOGAD were included and initially diagnosed with ADEM (n = 59), unilateral ON (n = 12), bilateral ON (n = 16), myelitis (n = 6), neuromyelitis optica spectrum disorder (n = 8) or encephalitis (n = 6). The median follow-up time was 3 years in monophasic and 5 years in relapsing patients. There was no significant association between disease course and MOG-IgG titers at onset, sex, age at presentation, or clinical phenotype. Seroconversion to MOG-IgG-negative within 2 years of the initial event showed a significant risk reduction for a relapsing disease course. Forty-two/one hundred sixteen patients (monophasic n = 26, relapsing n = 16) had serial MOG-IgG testing in years 1 and 2 after the initial event. In contrast to relapsing patients, monophasic patients showed a significant decrease of MOG-IgG titers during the first and second years, often with seroconversion to negative titers. During the follow-up, MOG-IgG titers were persistently higher in relapsing than in monophasic patients. Decrease in MOG-IgG of ≥3 dilution steps after the first and second years was shown to be associated with a decreased risk of relapses. In our cohort, no patient experienced a relapse after seroconversion to MOG-IgG-negative. Discussion: In this study, patients with declining MOG-IgG titers, particularly those with seroconversion to MOG-IgG-negative, are shown to have a significantly reduced relapse risk.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaNeurology - Neuroimmunology Neuroinflammation
Brojčani podacivol. 9, br. 6, e200035
e-ISSN2332-7812
DOIhttps://doi.org/10.1212/NXI.0000000000200035
URN:NBNurn:nbn:hr:105:425317
Datum objave publikacije2022-10-13
URL dokumentahttp://nn.neurology.org/lookup/doi/10.1212/NXI.0000000000200035
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje-Nekomercijalno-Bez prerada 4.0 međunarodna (CC BY-NC-ND 4.0)
Datum i vrijeme pohrane2023-08-23 08:27:30